- Headquarters
- Seattle, Washington
- Employees
- 11–50
- Founded
- 1985
- Business Model
- B2B
- Last Round
- Venture RoundJan 2010
- Rounds
- 1
About
Cascadian Therapeutics was a Seattle-based biopharmaceutical company focused on developing targeted therapies for cancer. The company developed tucatinib (ONT-380), a highly selective HER2 inhibitor for HER2-positive breast cancer. Cascadian was acquired by Seattle Genetics in February 2018 for $614 million; tucatinib subsequently received FDA approval as Tukysa in 2020.
Summary
Cascadian Therapeutics is a Biotech company based in Seattle, United States, founded in 1985. Its most recent funding was a Venture Round round in Jan 2010. Investors include Seagen (Seattle Genetics).
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2018
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform